Review
Open access
Oct 2026
To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission
Introduction HER2-targeted therapy (HER2-TT) has improved outcomes in HER2+ metastatic breast cancer (MBC) with increasing numbers of long-term survivors in complete response (CR). Little is known about discontinuing maintenance HER2-TT in these patients. Methods An online survey of physicians was conducted via the Bre...
Han-Yi Lee, W. Ong, V. Tjan-Heijnen et al.
· Breast · 0 citations